Garo H. Armen - Oct 13, 2021 Form 3 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role
Director
Signature
/s/ Christine Klaskin, attorney-in-fact
Stock symbol
INKT
Transactions as of
Oct 13, 2021
Transactions value $
$0
Form type
3
Date filed
10/20/2021, 06:57 PM
Previous filing
Sep 14, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INKT Common Stock 2.23M Oct 13, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding INKT Stock Option (Right to Buy) Oct 13, 2021 Common Stock 27.8K $0.02 Direct F1
holding INKT Stock Option (Right to Buy) Oct 13, 2021 Common Stock 27.8K $0.02 Direct F2
holding INKT Stock Option (Right to Buy) Oct 13, 2021 Common Stock 696K $0.01 Direct F3
holding INKT Stock Option (Right to Buy) Oct 13, 2021 Common Stock 835K $3.03 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an option to purchase shares of the common stock, which vests as to 30% of the underlying shares on November 19, 2021 and as to the remaining 70% of the underlying shares on November 19, 2022, in each case, generally subject to continued employment.
F2 Represents an option to purchase shares of the common stock, which vests on or about December 31, 2022, as to a portion of the underlying shares as determined by the achievement of certain milestones between January 1, 2019 and December 31, 2022, with 20% vesting upon achievement of five milestones, and an additional 5% vesting for each.
F3 Represents an option to purchase shares of the common stock, which vested as to 33% of the underlying shares on January 30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.
F4 Represents an option to purchase shares of the common stock, which vests as to 33% of the underlying shares on February 11, 2022, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney